Bayland Capital
Overview
Bayland Capital is a venture capital firm founded in 2019 with a background from the biopharmaceutical company Pharmaron. The firm specializes in equity investments within the biomedical sector, focusing on innovative life science companies, drug R&D platforms, novel therapeutics, and medical device companies globally.
Year Founded
2019
Portfolio Companies
6
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Ommo Technologies | Aug 2026 | Series A | Co-investor |
| NewBay Pharma | Apr 2026 | Series B | Co-investor |
| Cascade Pharmaceuticals, Inc. | Feb 2026 | Series C | Co-investor |
| BridGene Biosciences | Oct 2025 | Series B Extension | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Bayland Capital based?
Bayland Capital is headquartered in Beijing, China.
When was Bayland Capital founded?
Bayland Capital was founded in 2019.
How many portfolio companies does Bayland Capital have?
Bayland Capital has 6 portfolio companies in Caplight's dataset.
What are some companies in Bayland Capital's portfolio?
Recent investments visible on Caplight include Ommo Technologies, Ommo Technologies, NewBay Pharma, Cascade Pharmaceuticals, Inc., BridGene Biosciences.
What was Bayland Capital's most recent investment?
Bayland Capital's most recent investment on Caplight was in Ommo Technologies in 2026.
What sectors does Bayland Capital focus on?
Bayland Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Bayland Capital focus on?
Bayland Capital typically invests at the Mid stage.